SCHEMBL19848771

SCHEMBL19848771

COc1ccc(Cl)c(NC(O)N(C)c2cc(Nc3ccc(N4CCN(C)CC4)cc3)ncn2)c1Cl

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FGFR3 P22607 11/20 0.72
▸ LCK P06239 7/20 0.56
▸ FGFR1 P11362 4/20 0.53
▸ FGFR2 P21802 3/20 0.53
▸ FGFR4 P22455 3/20 0.53
▸ JAK2 O60674 2/20 0.53
▸ ABL1 P00519 2/20 0.53
▸ INSR P06213 2/20 0.53
▸ FYN P06241 2/20 0.53
▸ YES1 P07947 2/20 0.53
▸ LYN P07948 2/20 0.53
▸ RET P07949 2/20 0.53
▸ MET P08581 2/20 0.53
▸ ROS1 P08922 2/20 0.53
▸ KIT P10721 2/20 0.53
▸ SRC P12931 2/20 0.53
▸ BRAF P15056 2/20 0.53
▸ PDGFRA P16234 2/20 0.53
▸ FLT1 P17948 2/20 0.53
▸ TYK2 P29597 2/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22087495 0.84 LCK (0.71) FGFR3LCKCYP3A4CYP2C9CYP2C19
SCHEMBL374547 0.84 FGFR3 (1.00) FGFR3LCKFGFR1FGFR2FGFR4
SCHEMBL22132803 0.84 FGFR3 (0.72) FGFR3LCKFGFR1FGFR2FGFR4
SCHEMBL374521 0.80 FGFR3 (0.81) FGFR3LCKFGFR1FGFR2FGFR4
SCHEMBL374049 0.79 FGFR3 (1.00) FGFR3LCKFGFR1FGFR2FGFR4
SCHEMBL583166 0.78 FGFR3 (0.86) FGFR3LCKFGFR1FGFR2FGFR4
SCHEMBL374211 0.76 FGFR3 (0.87) FGFR3LCKFGFR1FGFR2FGFR4
SCHEMBL374643 0.75 FGFR3 (0.72) FGFR3LCKFGFR1FGFR2FGFR4
SCHEMBL374757 0.75 FGFR3 (0.80) FGFR3LCKFGFR1FGFR2FGFR4
SCHEMBL374413 0.74 FGFR3 (0.81) FGFR3LCKFGFR1FGFR2FGFR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2790718-B1 ANTAGONIST OF THE FIBROBLAST GROWTH FACTOR RECEPTOR 3 (FGFR3) FOR USE IN THE TREATMENT OR THE PREVENTION OF SKELETAL DISORDERS LINKED WITH ABNORMAL ACTIVATION OF FGFR3 INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECH MÉDICALE (INSERM) (FR) 2018-02-07 — — EP disclosed
Send feedback